Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cascinelli, N.
Right arrow Articles by Kirov, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cascinelli, N.
Right arrow Articles by Kirov, K.
Related Collections
Right arrow Sentinel lymph node

Annals of Surgical Oncology, Vol 7, Issue 6 469-474, Copyright © 2000 by Society of Surgical Oncology

ARTICLES

Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience

N. Cascinelli, F. Belli, M. Santinami, V. Fait, A. Testori, W. Ruka, R. Cavaliere, N. Mozzillo, C. R. Rossi, R. M. MacKie, O. Nieweg, M. Pace and K. Kirov
Department of Surgery, Istituto Nazionale Tumori, Milan, Italy.

BACKGROUND: We report the experience of the World Health Organization (WHO) Melanoma Program concerning sentinel lymph node (SLN) biopsy for detecting patients with occult regional nodal metastases to submit to selective regional node dissection. METHODS: From February 1994 to August 1998, in 12 centers of the WHO Melanoma Program, 892 SLN biopsies were performed in 829 patients with clinical stage I melanoma (male: 370; female: 459; median age: 50 years old). The location of the primary melanoma was as follows: trunk 35%; lower limbs, 45%; upper limbs, 18%; and head and neck, 2%. Blue dye injection for SLN identification was performed in all cases; preoperative lymphoscintigraphy was done in 440 patients, and an intra-operative probe for a radio-guided biopsy was used in 141 cases. Overall, the SLN identification rate was 88%. In 68% of the patients, only one SLN was identified, whereas two and three or more SLN were detected in 24% and 8% of the remaining cases, respectively. RESULTS: Overall SLN positivity rate was 18%. Intra-operative frozen section examination was performed in 39% of the cases and was helpful in detecting occult localizations only in 47% of the positive SLNs. Distribution of positive cases by primary thickness was as follows: < 1mm: 2%; 1-1.99 mm: 7%; 2-2.99 mm: 13%; and > or = 3 mm: 31%. Positive nonsentinel lymph nodes were found in 22% of cases with positive SLN submitted for selective dissection. No complications due to the procedure were registered. Of 710 patients who were evaluated, 40 (6%) presented a regional nodal relapse after a negative SLN biopsy and underwent a delayed therapeutic dissection. From the 710 enrolled cases, 638 (88.5%) were alive without evidence of disease at the time of this writing. A multivariate analysis showed SLN status as one of the most significant prognostic factors (P = .000) along with thickness (P = .001) and ulceration (P = .015) of primary tumor. CONCLUSIONS: These data confirm the feasibility and safety of the SLN technique for selecting patients to submit to a radical node dissection. The data represent the basis for a future trial by the WHO Melanoma Program in this field to evaluate the most appropriate surgical approach for treating patients with occult regional nodal metastases.


This article has been cited by other articles:


Home page
 JCOHome page
J. E. Gershenwald, R. H.I. Andtbacka, V. G. Prieto, M. M. Johnson, A. H. Diwan, J. E. Lee, P. F. Mansfield, J. N. Cormier, C. W. Schacherer, and M. I. Ross
Microscopic Tumor Burden in Sentinel Lymph Nodes Predicts Synchronous Nonsentinel Lymph Node Involvement in Patients With Melanoma
J. Clin. Oncol., September 10, 2008; 26(26): 4296 - 4303.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
Y. Liu, C. Truini, and S. Ariyan
A Randomized Study Comparing the Effectiveness of Methylene Blue Dye with Lymphazurin Blue Dye in Sentinel Lymph Node Biopsy for the Treatment of Cutaneous Melanoma
Ann. Surg. Oncol., September 1, 2008; 15(9): 2412 - 2417.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
Z. I. Nowecki, P. Rutkowski, and W. Michej
The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2-pT3)
Ann. Surg. Oncol., August 1, 2008; 15(8): 2223 - 2234.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
I. Koskivuo, L. Talve, P. Vihinen, M. Maki, T. Vahlberg, and E. Suominen
Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Case-Control Study
Ann. Surg. Oncol., December 1, 2007; 14(12): 3566 - 3574.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
B. Badgwell, Y. Xing, J. E. Gershenwald, J. E. Lee, P. F. Mansfield, M. I. Ross, and J. N. Cormier
Pelvic Lymph Node Dissection Is Beneficial in Subsets of Patients with Node-positive Melanoma
Ann. Surg. Oncol., October 1, 2007; 14(10): 2867 - 2875.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T. G. Zogakis, R. Essner, H.-j. Wang, L. J. Foshag, and D. L. Morton
Natural History of Melanoma in 773 Patients with Tumor-Negative Sentinel Lymph Nodes
Ann. Surg. Oncol., May 1, 2007; 14(5): 1604 - 1611.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
Z. I. Nowecki, P. Rutkowski, A. Nasierowska-Guttmejer, and W. Ruka
Survival Analysis and Clinicopathological Factors Associated With False-Negative Sentinel Lymph Node Biopsy Findings in Patients with Cutaneous Melanoma
Ann. Surg. Oncol., December 1, 2006; 13(12): 1655 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. Mocellin, A. Ambrosi, M. C. Montesco, M. Foletto, G. Zavagno, D. Nitti, M. Lise, and C. R. Rossi
Support Vector Machine Learning Model for the Prediction of Sentinel Node Status in Patients With Cutaneous Melanoma
Ann. Surg. Oncol., August 1, 2006; 13(8): 1113 - 1122.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
G. C. Karakousis, P. A. Gimotty, J. D. Botbyl, S. B. Kesmodel, D. E. Elder, R. Elenitsas, M. E. Ming, D. Guerry, D. L. Fraker, B. J. Czerniecki, et al.
Predictors of Regional Nodal Disease in Patients With Thin Melanomas
Ann. Surg. Oncol., April 1, 2006; 13(4): 533 - 541.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. I. Ross
Early-stage melanoma: staging criteria and prognostic modeling.
Clin. Cancer Res., April 1, 2006; 12(7): 2312s - 2319s.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. Vaquerano, W. G. Kraybill, D. L. Driscoll, R. Cheney, and J. M. Kane III
American Joint Committee on Cancer Clinical Stage as a Selection Criterion for Sentinel Lymph Node Biopsy in Thin Melanoma
Ann. Surg. Oncol., February 1, 2006; 13(2): 198 - 204.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
N. Nathansohn, J. Schachter, and H. Gutman
Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection
Arch Surg, December 1, 2005; 140(12): 1172 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
T. G. Zogakis, R. Essner, H.-j. Wang, R. R. Turner, Y. T. Takasumi, R. L. Gaffney, J. H. Lee, and D. L. Morton
Melanoma Recurrence Patterns After Negative Sentinel Lymphadenectomy
Arch Surg, September 1, 2005; 140(9): 865 - 872.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. van Poll, J. F. Thompson, M. H. Colman, J. G. McKinnon, R. P. M. Saw, J. R. Stretch, R. A. Scolyer, and R. F. Uren
A Sentinel Node Biopsy Does Not Increase the Incidence of In-Transit Metastasis in Patients With Primary Cutaneous Melanoma
Ann. Surg. Oncol., August 1, 2005; 12(8): 597 - 608.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
V. S.K. Yee, J. F. Thompson, J. G. McKinnon, R. A. Scolyer, L.-X. L. Li, W. H. McCarthy, C. J. O'Brien, M. J. Quinn, R. P.M. Saw, K. F. Shannon, et al.
Outcome in 846 Cutaneous Melanoma Patients From a Single Center After a Negative Sentinel Node Biopsy
Ann. Surg. Oncol., June 1, 2005; 12(6): 429 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. B. Kesmodel, G. C. Karakousis, J. D. Botbyl, R. J. Canter, R. T. Lewis, P. M. Wahl, K. P. Terhune, A. Alavi, D. E. Elder, M. E. Ming, et al.
Mitotic Rate as a Predictor of Sentinel Lymph Node Positivity in Patients With Thin Melanomas
Ann. Surg. Oncol., June 1, 2005; 12(6): 449 - 458.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
M. C Swan, D. Furniss, and O. C S Cassell
Surgical management of metastatic inguinal lymphadenopathy
BMJ, November 27, 2004; 329(7477): 1272 - 1276.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
K. B. Stitzenberg, P. A. Groben, S. L. Stern, N. E. Thomas, T. A. Hensing, L. B. Sansbury, and D. W. Ollila
Indications for Lymphatic Mapping and Sentinel Lymphadenectomy in Patients with Thin Melanoma (Breslow Thickness <=1.0 mm)
Ann. Surg. Oncol., October 1, 2004; 11(10): 900 - 906.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. Doubrovsky, J.H.W. de Wilt, R.A. Scolyer, W.H. McCarthy, and J.F. Thompson
Sentinel Node Biopsy Provides More Accurate Staging Than Elective Lymph Node Dissection in Patients With Cutaneous Melanoma
Ann. Surg. Oncol., September 1, 2004; 11(9): 829 - 836.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
C. M. Balch, S.-J. Soong, M. B. Atkins, A. C. Buzaid, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton Jr., J. M. Kirkwood, et al.
An Evidence-based Staging System for Cutaneous Melanoma
CA Cancer J Clin, May 1, 2004; 54(3): 131 - 149.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
V. K. Sondak, J. M. G. Taylor, M. S. Sabel, Y. Wang, L. Lowe, A. C. Grover, A. E. Chang, A. M. Yahanda, J. Moon, and T. M. Johnson
Mitotic Rate and Younger Age Are Predictors of Sentinel Lymph Node Positivity: Lessons Learned From the Generation of a Probabilistic Model
Ann. Surg. Oncol., March 1, 2004; 11(3): 247 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. A. Scolyer, J. F. Thompson, L.-X. L. Li, A. Beavis, M. Dawson, P. Doble, V. S. K. Ka, J. Gregory McKinnon, R. Soper, R. F. Uren, et al.
Failure to Remove True Sentinel Nodes Can Cause Failure of the Sentinel Node Biopsy Technique: Evidence from Antimony Concentrations in False-Negative Sentinel Nodes from Melanoma Patients
Ann. Surg. Oncol., March 1, 2004; 11(3_suppl): 174S - 178S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
O. Alonso, M. Martinez, L. Delgado, A. De Leon, D. De Boni, G. Lago, M. Garces, F. Fontes, J. Espasandin, and J. Priario
Staging of Regional Lymph Nodes in Melanoma Patients by Means of 99mTc-MIBI Scintigraphy
J. Nucl. Med., October 1, 2003; 44(10): 1561 - 1565.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. H. Estourgie, O. E. Nieweg, R. A. Valdes Olmos, C. A. Hoefnagel, and B. B. R. Kroon
Review and Evaluation of Sentinel Node Procedures in 250 Melanoma Patients With a Median Follow-Up of 6 Years
Ann. Surg. Oncol., July 1, 2003; 10(6): 681 - 688.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
G. W. Carlson, D. R. Murray, A. Hestley, C. A. Staley, R. H. Lyles, and C. Cohen
Sentinel Lymph Node Mapping for Thick (>=4-mm) Melanoma: Should We Be Doing It?
Ann. Surg. Oncol., May 1, 2003; 10(4): 408 - 415.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. Simmons, S. Thevarajah, M. B. Brennan, P. Christos, and M. Osborne
Methylene Blue Dye as an Alternative to Isosulfan Blue Dye for Sentinel Lymph Node Localization
Ann. Surg. Oncol., April 1, 2003; 10(3): 242 - 247.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R.J.C.L.M. Vuylsteke, P.A.M. van Leeuwen, M.G. S. Muller, H.A. Gietema, D.R. Kragt, and S. Meijer
Clinical Outcome of Stage I/II Melanoma Patients After Selective Sentinel Lymph Node Dissection: Long-Term Follow-Up Results
J. Clin. Oncol., March 15, 2003; 21(6): 1057 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. E. Reeves, R. Delgado, K. J. Busam, M. S. Brady, and D. G. Coit
Prediction of Nonsentinel Lymph Node Status in Melanoma
Ann. Surg. Oncol., January 1, 2003; 10(1): 27 - 31.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
C. E. Schmalbach, B. Nussenbaum, R. S. Rees, J. Schwartz, T. M. Johnson, and C. R. Bradford
Reliability of Sentinel Lymph Node Mapping With Biopsy for Head and Neck Cutaneous Melanoma
Arch Otolaryngol Head Neck Surg, January 1, 2003; 129(1): 61 - 65.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. Mariani, M. Gipponi, L. Moresco, G. Villa, M. Bartolomei, G. Mazzarol, M. C. Bagnara, A. Romanini, F. Cafiero, G. Paganelli, et al.
Radioguided Sentinel Lymph Node Biopsy in Malignant Cutaneous Melanoma*
J. Nucl. Med., June 1, 2002; 43(6): 811 - 827.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
K. M. McMasters, C. Chao, S. L. Wong, W. R. Wrightson, M. I. Ross, D. S. Reintgen, R. D. Noyes, P. B. Cerrito, M. J. Edwards, and for the Sunbelt Melanoma Trial Group
Interval Sentinel Lymph Nodes in Melanoma
Arch Surg, May 1, 2002; 137(5): 543 - 549.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U.N.M. Rao, J. Ibrahim, L.E. Flaherty, J. Richards, and J.M. Kirkwood
Implications of Microscopic Satellites of the Primary and Extracapsular Lymph Node Spread in Patients With High-Risk Melanoma: Pathologic Corollary of Eastern Cooperative Oncology Group Trial E1690
J. Clin. Oncol., April 15, 2002; 20(8): 2053 - 2057.
[Abstract] [Full Text] [PDF]

Home page
 ImagingHome page
P J Ell
A revolution in surgical oncology: sentinel lymph node biopsy
Imaging, September 1, 2001; 13(3): 197 - 205.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
R. W. Dubois, S. M. Swetter, M. Atkins, K. McMasters, R. Halbert, S. J. Miller, R. Shiell, and J. Kirkwood
Developing Indications for the Use of Sentinel Lymph Node Biopsy and Adjuvant High-Dose Interferon Alfa-2b in Melanoma
Arch Dermatol, September 1, 2001; 137(9): 1217 - 1224.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Balch, A. C. Buzaid, S.-J. Soong, M. B. Atkins, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton Jr, J. M. Kirkwood, et al.
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
J. Clin. Oncol., August 15, 2001; 19(16): 3635 - 3648.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. S. Krouse, R. E. Schwarz, and S. P. L. Leong
Blue Dye for Sentinel Lymph Node Mapping: Not Too Sensitive, but Too Hypersensitive?
Ann. Surg. Oncol., April 1, 2001; 8(3): 268 - 269.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the Society of Surgical Oncology.